Soluble HER2 promotes chronic antigen-mediated CD8(+) T-cell dysfunction and limits immunotherapy response in HER2-low triple-negative breast cancer.
HER2-low triple-negative breast cancer (TNBC) has emerged as a clinically relevant subgroup with distinct therapeutic implications. Clinically, HER2-low tumors showed a significantly reduced pathological complete response rate following PD-1-based immunotherapy.
HER2-low triple-negative breast cancer (TNBC) has emerged as a clinically relevant subgroup with distinct therapeutic implications. Clinically, HER2-low tumors showed a significantly reduced pathological complete response rate following PD-1-based immunotherapy.
What the study was
- Study design
- Retrospective study
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cell death & disease
Why it surfaced
Relevant Novel therapeutics: immunotherapy, CAR-T, targeted therapy study (promising preliminary signal) meets standard-priority threshold.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.